-
Product Name
ENT1 antibody
- Documents
-
Description
ENT1 Rabbit Polyclonal antibody. Positive IHC detected in human breast cancer tissue. Positive IP detected in mouse brain tissue. Positive WB detected in mouse brain tissue, human liver tissue, human lung tissue, human spleen tissue, mouse kidney tissue, mouse liver tissue, mouse lung tissue, mouse testis tissue. Observed molecular weight by Western-blot: 62 kDa
-
Tested applications
ELISA, WB, IHC, IP
-
Species reactivity
Human,Mouse,Rat; other species not tested.
-
Alternative names
ENT1 antibody; SLC29A1 antibody
-
Isotype
Rabbit IgG
-
Preparation
This antibody was obtained by immunization of ENT1 recombinant protein (Accession Number: XM_005248881). Purification method: Antigen affinity purified.
-
Clonality
Polyclonal
-
Formulation
PBS with 0.1% sodium azide and 50% glycerol pH 7.3.
-
Storage instructions
Store at -20℃. DO NOT ALIQUOT
-
Applications
Recommended Dilution:
WB: 1:200-1:2000
IP: 1:200-1:1000
IHC: 1:20-1:200
-
Validations
mouse brain tissue were subjected to SDS PAGE followed by western blot with Catalog No:110328(ENT1 antibody) at dilution of 1:500
IP Result of anti-ENT1 (IP:Catalog No:110328, 3ug; Detection:Catalog No:110328 1:400) with mouse brain tissue lysate 8000ug.
Immunohistochemical of paraffin-embedded human breast cancer using Catalog No:110328(ENT1 antibody) at dilution of 1:100 (under 10x lens)
-
Background
ENT1 (equilibrative nucleoside transporter 1; also known as SLC29A1) is a ubiquitous protein located at the cell membrane and is a major transporter responsible for the cellular uptake and release of endogenous nucleosides such as adenosine, and nucleoside analogs used in chemotherapy. Higher level of human ENT1 expression in tumor cells has been associated with prolonged survival in patients receiving gemcitabine (22426593). The predicted molecular weight of ENT1 is 50 kDa, while heavier 54-62 kDa band may be observed due to the glycosylation (16448802, 11850433). A smaller novel splice variant of the mouse ENT1 has also been identified, which generates a protein of 35-40 kDa (18413666).
-
References
- Komori S, Osada S, Mori R. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer. Pancreas. 39(8):1284-92. 2010.
- Matsumura N, Nakamura Y, Kohjimoto Y. The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. BJU international. 108(2 Pt 2):E110-6. 2011.
- Okuda H, Higashi Y, Nishida K, Fujimoto S, Nagasawa K. Contribution of P2X7 receptors to adenosine uptake by cultured mouse astrocytes. Glia. 58(14):1757-65. 2010.
- Tanaka A, Nishida K, Okuda H. Peroxynitrite treatment reduces adenosine uptake via the equilibrative nucleoside transporter in rat astrocytes. Neuroscience letters. 498(1):52-6. 2011.
- Kawada N, Uehara H, Katayama K. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine. Journal of hepato-biliary-pancreatic sciences. 19(6):717-22. 2012.
- Nishida K, Kitada T, Kato J, Dohi Y, Nagasawa K. Expression of equilibrative nucleoside transporter 1 in rat circumvallate papillae. Neuroscience letters. 533:104-8. 2013.
- Murata A, Amano R, Yamada N. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone. World journal of surgical oncology. 11:117. 2013.
- Hummel-Eisenbeiss J, Hascher A, Hals PA. The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells. Molecular pharmacology. 84(3):438-50. 2013.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"